Prime Medicine, Inc. Common Stock (PRME) Stock Price

PRMEStock

$3.61+4.94%52W

Market Cap$654.77M

P/E—

PEG Ratio—

Div yield—

Beta2.33

PRME Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-17.67%

Price vs S&P 500 (4W)26.93%

VGM Score37.43

Book Value / Share (Quarterly)$0.22

P/TBV (Annual)2.14x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-16.96%

Cash Flow / Share (Quarterly)$-0.87

Price vs S&P 500 (YTD)-8.79%

Net Profit Margin (TTM)-4613.11%

EPS (TTM)$-1.09

10-Day Avg Trading Volume2.90M

EPS Excl Extra (TTM)$-1.09

EPS (Annual)$-1.35

ROI (Annual)-166.41%

Cash / Share (Quarterly)$0.53

Revenue Growth QoQ (YoY)3.50%

ROA (Last FY)-58.69%

Revenue Growth TTM (YoY)-17.90%

EBITD / Share (TTM)$-1.09

ROE (5Y Avg)-110.15%

Operating Margin (TTM)-4824.94%

Cash Flow / Share (Annual)$-0.93

P/B Ratio14.44x

P/B Ratio (Quarterly)16.74x

Net Income / Employee (Annual)$-1,377,700

EV / Revenue (TTM)129.51x

Net Interest Coverage (TTM)-82.30x

ROA (TTM)-59.11%

EPS Incl Extra (Annual)$-1.35

Current Ratio (Annual)4.84x

Quick Ratio (Quarterly)3.01x

3-Month Avg Trading Volume3.04M

52-Week Price Return4.94%

Revenue / Employee (TTM)$27,900

Tangible BV / Share (Quarterly)$1.99

P/S Ratio (Annual)124.13x

Asset Turnover (Annual)0.01x

52-Week High$6.94

EPS Excl Extra (Annual)$-1.35

CapEx CAGR (5Y)47.91%

26-Week Price Return-5.74%

Quick Ratio (Annual)4.76x

13-Week Price Return6.18%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.05x

Enterprise Value$527.51M

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$31,700

Pretax Margin (Annual)-4342.44%

Cash / Share (Annual)$0.98

3-Month Return Std Dev90.74%

Net Income / Employee (TTM)$-1,286,900

ROE (Last FY)-166.41%

Net Interest Coverage (Annual)-25.03x

EPS Basic Excl Extra (Annual)$-1.35

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.09

ROI (TTM)-188.27%

P/S Ratio (TTM)141.16x

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$3.25

Price vs S&P 500 (52W)-13.62%

Year-to-Date Return4.03%

5-Day Price Return11.08%

EPS Normalized (Annual)$-1.35

ROA (5Y Avg)-63.07%

Net Profit Margin (Annual)-4342.44%

Month-to-Date Return23.63%

Cash Flow / Share (TTM)$-1.79

EBITD / Share (Annual)$-1.35

Operating Margin (Annual)-4498.06%

ROI (5Y Avg)-110.15%

EPS Basic Excl Extra (TTM)$-1.09

P/TBV (Quarterly)3.49x

P/B Ratio (Annual)5.18x

Pretax Margin (TTM)-4613.11%

Book Value / Share (Annual)$0.67

Price vs S&P 500 (13W)4.22%

Beta2.33x

Revenue / Share (TTM)$0.02

ROE (TTM)-188.27%

52-Week Low$2.67

vGradeF

gGradeD

mGradeB

vgmGradeD

PRME Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.26	-$0.24	+6.00%(+$0.02)
Q1 2026	May 7, 2026	-$0.25	-$0.28	-12.59%(-$0.03)
Q4 2025	Mar 3, 2026	-$0.26	-$0.24	+6.92%(+$0.02)
Q3 2025	Nov 7, 2025	-$0.25	-$0.32	-29.43%(-$0.07)
Q2 2025	Aug 7, 2025	-$0.34	-$0.41	-20.60%(-$0.07)

PRME Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.05

4.11

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
PRMEPrime Medicine, Inc. Common Stock	F	D	B	$3.61
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Prime Medicine, Inc. Common Stock

Prime Medicine Inc develops genetic therapies based on Prime Editing, a next-generation gene-editing technology designed to precisely correct genetic mutations and restore normal cellular function. The company targets rare and severe diseases with significant unmet medical needs across multiple therapeutic areas. Prime Editing's broader applicability compared to earlier gene-editing approaches positions the company to address a substantial market opportunity.